Genentech to onshore US manufacturing amid rising drug pricing tensions
Genentech (San Francisco, CA) has announced an investment exceeding $700m to establish its first East Coast manufacturing facility in Holly …
Post
-
-
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
Roche’s blockbuster vision for phosphoinositide 3-kinase (PI3K inhibitor) Itovebi (inavolisib) has been dealt a boost after the drug demonstrated further …
-
NICE endorses CSL Vifor’s sparsentan for IgA nephropathy in adults
The UK's National Institute for Health and Care Excellence (NICE) has issued final draft guidance endorsing the use of CSL …
-
Obesity therapies and the multi-indication momentum: how industry is responding
The obesity therapeutics market has gone from a standing start to the story of the year in biopharmaceuticals - and …
-
Medicaid on a spit after Republicans’ budget bill passes House by single vote
The Trump administration’s budget reconciliation bill has passed the US House of Representatives by a wafer-thin single-vote majority. Passing the House …
-
Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo
Bayer’s retinal disease treatment Eylea (aflibercept) is set for an extended treatment interval, a label extension that could give the …
-
FDA approves GSK’s Nucala to treat COPD
GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as an …
-
Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection
Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting renal, cardiovascular and metabolic conditions such as chronic …
-
Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push
Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in …
-
Paratek expands commercial portfolio with Optinose
Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings. The companies signed a …
-
Wegovy and Zepbound costs capped at $200 in new Evernorth programme
Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with drugmakers Novo Nordisk and Eli …
-
Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia
Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for Kisunla (donanemab) to treat …
-
UK biopharma innovator venture financing surges to $1.1bn in Q1 2025
UK biopharmaceutical companies saw a surge in venture financing for innovator drugs in 2024, with double the total deal value …
-
Overcoming cold-chain logistical challenges when delivering life-saving MS therapies
With the MS Trust estimating that more than 2.9 million people worldwide have multiple sclerosis (MS), new therapies are urgently …
-
Orionis and Genentech link on oncology small-molecule glue medicines
Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue …
